MULTIPLE MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES

International Conference on
MULTIPLE MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES

Chairs: J.L. Harousseau (Nantes), J. San Miguel (Salamanca), M. Boccadoro (Turin)
Local organiser: A. Parreira

6-9 March 2008 - Cascais, Portugal
Thursday, March 6, 2008
19h00: Welcome cocktail and dinner

Friday, March 7, 2008
Session 1 : Genetic Changes in Multiple Myeloma
10h00-10h30: Genetic Events in Multiple Myeloma, L. Bergsagel (Scottsdale/USA)
10h30-11h00: Prognostic implications of cytogenetic abnormalities, H. Avet-Loiseau (Nantes)
11h00-11h30: Gene expression profiling in Multiple Myeloma, J. Shaughnessy (Little Rock/USA)
11h30-12h00: SNIP and CGH arrays in Multiple Myeloma, G. Morgan (London)

Session 2 : The malignant plasma cell in its microenvironment
13h00-13h30: Phenotype of the malignant plasma cell, A. Orfao (Salamanca)
13h30-14h00: Signal Transduction Pathways, M. Amiot (Nantes)
14h00-14h30: Angiogenesis in Multiple Myeloma, A. Vacca (Bari)
14h30-15h00: Bone Disease. Pathophysiology and Treatment, E. Terpos (Athens)
15h00-15h30: Coffee break

Session 3 : Clinical Aspects of Multiple Myeloma
15h30-16h00: From Monoclonal Gammopathy of Unknown Significance to Plasma Cell Leukemia J. Blade (Barcelona)
16h00-16h30: Prognostic Factors N. Zojer (Vienna)
16h30-17h00: New tools for response assessment and prognostic value of CR achievement J.L Harousseau (Nantes)
17h00-17h30: Renal Impairment J.P. Fermand (Paris)

Saturday, March 8, 2008
Session 4 : Therapeutic Agents in Multiple Myeloma
09h30-10h00: Thalidomide. Mode of action, toxicity, efficacy in relapsed Multiple Myeloma. M. Kropf
10h00-10h30: Bortezomib. Mode of action, toxicity, efficacy in relapsed Multiple Myeloma. P. Moreau (Nantes)
10h30-11h00: Lenalidomide. Mode of action, toxicity, efficacy in relapsed Multiple Myeloma. M. Dimopoulos (Athens)
11h00-11h30: Coffee break
11h30-12h00: Combinations of novel agents (imids + Bortezomib) M. Boccadoro (Turin)
12h00-12h30: Immune Therapy in Multiple Myeloma N. Munshi (Boston)
12h30-13h00: Novel Agents in development J. San Miguel (Salamanca)

13h00-14h00: Lunch

Session 5 : Therapeutic Strategies
14h00-14h30: Treatment of elderly patients C. Hulin (Nancy)
14h30-15h00: Can novel agents replace autologous transplantation in younger patients ? K. Shaji (Rochester/USA)

15h00-15h30: Role of Autologous Stem Cell Transplantation in frontline therapy M. Attal (Toulouse)

15h30-16h00: Coffee break

16h00-16h30: Role of Allogeneic Stem Cell Transplantation N. Kroger (Hamburg)
16h30-17h00: Therapeutic strategies in relapsed Multiple Myeloma P. Sonneveld (Rotterdam)
17h00-17h30: Quality of Life Assessment in Multiple Myeloma F. Wisloff (Ulleval)

Sunday, March 9, 2008

Session 6 : Other Monoclonal Gammopathies
10h00-10h30: Amyloidosis G. Merlini (Pavia)
10h30-11h00: New advances in the biology of Waldenstrom’s Macroglobulinemia G. Pangalis (Athens)
11h00-11h30: Prognosis and Treatment of Waldenstroem Macroglobulinemia S. Treon (Boston/USA)
11h30-12h30: Panel discusssion
12: 00: MEETING CLOSURE